Pfizer, Merck KGaA run into a severe setback as PD-L1 drug Bavencio fails in PhIII gastric cancer study
Pfizer $PFE and its partner Merck KGaA have run into a dead end in their race to expand the market for their PD-L1 checkpoint Bavencio …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.